John Park, MD
Ophthalmology · Edison, NJNPI 1255372827
Payments from drug & device makers
Across 661 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- NEW World Medical,inc.$2K
- Sun Pharmaceutical Industries Inc.$2K
- Alcon$1K
- Glaukos Corporation$1K
- Bausch & Lomb Americas Inc.$944
- plus $6K from 26 others
What the payments were for
- Speaking & faculty fees$2021%
- Food & beverage$14,50699%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 119 | $2,301 |
| NEW World Medical,inc. | 14 | $2,127 |
| Sun Pharmaceutical Industries Inc. | 91 | $1,525 |
| Alcon | 61 | $1,080 |
| Glaukos Corporation | 8 | $1,030 |
| Bausch & Lomb Americas Inc. | 39 | $944 |
| Oyster Point Pharma, Inc. | 45 | $782 |
| Novartis | 70 | $688 |
| Sight Sciences, Inc. | 24 | $582 |
| Mallinckrodt Hospital Products Inc. | 18 | $496 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 34 | $435 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $392 |
| Ocular Therapeutix, Inc. | 18 | $357 |
| Kala Pharmaceuticals, Inc. | 23 | $347 |
| Harrow Eye, LLC | 16 | $227 |
| Dompe US, Inc. | 13 | $208 |
| Notal Vision, Inc. | 2 | $202 |
| ANI Pharmaceuticals, Inc. | 8 | $133 |
| Tarsus Pharmaceuticals, Inc. | 7 | $129 |
| Eyevance Pharmaceuticals LLC | 8 | $114 |
| Aerie Pharmaceuticals, Inc. | 7 | $101 |
| Shire North American Group Inc | 6 | $86 |
| Thea Pharma Inc. | 5 | $82 |
| Biotissue Holdings Inc. | 3 | $76 |
| Coopervision Inc. | 3 | $70 |
| Amgen | 3 | $53 |
| Ivantis, Inc | 2 | $46 |
| Aerin Medical Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Alimera Sciences, Inc. | 1 | $17 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Eyepoint US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$1,813
- Streamline Surgical System$1,813
- Ahmed Glaucoma Valve$1,813
- enVista MX60 IOL$436
- CEQUA$250
- ACTHAR$237
- LUMIGAN$229
- enVista Aspire IOL$218
- iDose$147
- Tecnis IOL$142
- RESTASIS MULTIDOSE$128
- iStent inject W$126
- KXL System$126
- Photrexa$126
- iStent inject Trabecular Micro-Bypass Stent System$125
- OMNI(R) SURGICAL SYSTEM (US)$123
- COMBIGAN$122
- Tecnis Simplicity$117
- DURYSTA$107
- XEN GLAUCOMA TREATMENT SYSTEM$107
How this compares
$14,726 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 704 | $683,789 |
| XiidraLifitegrast | 442 | $465,646 |
| Cyclosporine | 425 | $239,454 |
| LumiganBimatoprost | 319 | $172,279 |
| CequaCyclosporine | 90 | $65,166 |
| CombiganBrimonidine Tartrate/Timolol | 80 | $32,935 |
| Prednisolone Acetate | 690 | $32,293 |
| TyrvayaVarenicline Tartrate | 36 | $32,182 |
| VevyeCyclosporine | 29 | $28,964 |
| MieboPerfluorohexyloctane/Pf | 37 | $28,836 |
| Alphagan PBrimonidine Tartrate | 43 | $23,143 |
| VyzultaLatanoprostene Bunod | 27 | $15,015 |
| Brimonidine Tartrate | 288 | $14,438 |
| ProlensaBromfenac Sodium | 32 | $13,834 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 58 | $13,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $2,301 | $912,1471,146 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $944 | $509,498506 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,525 | $65,16690 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $782 | $32,18236 claims |
| Harrow Eye, LLCVevye | $227 | $28,96429 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $101 | $20,61348 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Loteprednol Etabonate | $435 | $18,96657 claims |
| AlconSimbrinza | $1,080 | $13,05258 claims |
| Thea Pharma Inc.Iyuzeh | $82 | $6,76122 claims |
| NovartisIlevro | $688 | $4,92014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Edison
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.